|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 37/04 | (2006.01) |
| (11) | Number of the document | 3512547 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17772258.4 |
| Date of filing the European patent application | 2017-09-14 | |
| (97) | Date of publication of the European application | 2019-07-24 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-11 |
| (46) | Date of publication of the claims translation | 2021-01-11 |
| (86) | Number | PCT/US2017/051531 |
| Date | 2017-09-14 |
| (87) | Number | WO 2018/053106 |
| Date | 2018-03-22 |
| (30) | Number | Date | Country code |
| 201662394314 P | 2016-09-14 | US |
| (72) |
AFAR, Daniel E. H., US
HARDING, Fiona A., US
SAMAYOA, Josue, US
|
| (73) |
AbbVie Biotherapeutics Inc.,
1500 Seaport Boulevard, Redwood City, CA 94063,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūnai prieš PD-1 |
| ANTI-PD-1 ANTIBODIES |
| Payment date | Validity (years) | Amount | |
| 2025-08-25 | 9 | 208.00 EUR |
| 2026-09-14 |